CellPly announces acceptance of one abstract at the CICON23 conference

BOLOGNA, Italy, September 18, 2023 – CellPly, the pioneer in multiparametric single-cell analysis and automated potency testing for cell therapy, today announced that it will present data in a poster presentation at the Seventh International Cancer Immunotherapy Conference: Translating Science into Survival, being held in Milan, Italy, on Sep. 20-23, 2023.

The data reported in this abstract, generated within a scientific collaboration with the team of Dr. Richard Harbottle at the DKFZ institute, Heidelberg, Germany, show the characterization of TCR-T cells engineered from Dr. Harbottle’s team through the VivaCyte® technology for the analysis of cell function at the single-cell resolution developed at Cellply. Thanks to a novel single-cell serial killing assay, researchers were able to demonstrate that T cells engineered with a non-viral DNA nanovector acquire the capacity to exert their cytotoxic function multiple times before their exhaustion, leading to an increase in T cell potency.

Details of the poster presentation are as follows:

Title: Single-cell cytotoxicity analysis identifies serial killer transgenic TCR-T cells manufactured using non-viral S/MAR DNA nanovectors
Abstract number: P528
Session: POSTER SESSION A – EVEN NUMBERS Thursday, Sept. 21
Link to abstract

About Cellply
CellPly is a life-science company developing analytical tools aiming at unraveling the complexity of the immune system and enabling rapid and effective development of next-generation immunotherapies and cell-based therapies. Our unique solution combines a proprietary microfluidic technology to capture functional and phenotypic information from thousands of single cells, with the highly automated VivaCyte® analytical instrument, integrating robotic solutions and AI for image analysis. Our goal is to make in-depth analysis applicable across the therapy development cycle, from discovery to process development and quality control.

Contacts
press@cellply.com

Follow us
LinkedIn: https://www.linkedin.com/company/cellply
Twitter: https://twitter.com/cellply

September 18, 2023 Events, Publications No comments yet

L’innovazione Cellply in un articolo sulla rivista Le Scienze

Cliccare sull’immagine in basso per visualizzare l’articolo

March 4, 2020 Publications, Science No comments yet

Cellply to present new method for evaluating immunotherapy efficacy at the 61th ASH Annual Meeting

Bologna (Italy), 25 November 2019.

Cellply announced today that the company will present an abstract with new results about its novel Inter-Cell Networking Profiling (ICNP) technology at the 61th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 7-10 in Orlando, FL, USA.

“There is an unmet need in oncology to expand current precision medicine approaches to cancer immunotherapy” says Massimo Bocchi, CEO at Cellply. “The work we will present at the next ASH congress represents an important step forward in the combined evaluation of drug action and immune system activity. Our work, leveraging on our unique ability to generate thousands of microtumors in a single automated test and select the cell networks better mimicking the in-vivo cell behavior, provides an unprecedented method to screen antibody therapies with immune-mediated mechanisms of action. Starting from these results we are currently working with biopharmaceutical companies and research institutes to generate novel and effective immuno-oncology therapeutics”.

The abstract is the results of a scientific collaboration with hematologists and scientists from Prof. Cavo’s team working on Multiple Myeloma at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy). The work is supported by the ONCOSMART project, funded by the European Commission under the SME Instrument (Phase 2) programme.

Title: Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients
Authors: Alice Bettelli, Rita Ruggiano, Silvia Bocchi, Laura Rocchi, Andrea Faenza, Enrica Borsi, Carolina Terragna, Elena Zamagni, Marina Martello, Marco Bettelli, Laura Rambelli, Viviana Guadagnuolo, Nicola Pecorari, Luca Giulianelli, Matteo Pisani, Dario Biscarini, Michele Cavo, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 3372
Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2 (Orange County Convention Center)
Session: 803. Emerging Diagnostic Tools and Techniques: Poster II

Link to abstract

Download poster

November 25, 2019 Events, Publications No comments yet

Cellply abstract accepted at the AACR 2018 Annual Meeting

Bologna (Italy), 4 February 2018

Cellply will present results of clinical testing activities on Acute Myeloid Leukemia patients at the American Association for Cancer Research (AACR) 2018 Annual Meeting, taking place April 14-18 in Chicago.

Results of the study, conducted in collaboration with haematologists and researchers at the Sant’Orsola-Malpighi Polyclinic in Bologna, show the high accuracy obtained with Cellply’s platform in predicting standard therapy outcome.

Title: Lab-on-a-chip-based in-vitro functional profiling proves to be effective in predicting therapy outcome in AML patients
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 3613
Date/Time: Tuesday Apr 17, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 25
Session Category: Clinical Research
Session Title: Biomarker Discovery 4

Link to abstract

View poster online

February 4, 2018 Events, Publications No comments yet

Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

Bologna (Italy), 4 November 2016.

Cellply announced today that the results of a scientific collaboration with hematologists at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy) working on Acute Myeloid Leukemia (AML), a group led by Prof. Giovanni Martinelli, will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 3-6 in San Diego, CA, USA. “This is a key milestone for our company as it shows the potential of the Open Microwell technology and the IVD platform under development at Cellply to become an important tool for guiding the identification of the appropriate treatment for each patient or patient set through the analysis of biological information that today remain mostly not exploited for patient stratification”, says Massimo Bocchi, CEO of Cellply. “The preliminary data collected within this scientific activity provided good correlation between our test and the clinical outcome, making Cellply’s platform promising for predicting the haematological response, an endpoint of primary importance not only from a clinical standpoint but also for its use within clinical trials”, added Laura Rocchi, Head of Biology at Cellply. The following abstract was accepted for poster presentation by the American Society of Hematology.

Title: Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 1675
Date/Time: Saturday, December 3, 2016, 5:30 PM-7:30 PM
Location: Hall GH (San Diego Convention Center)
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Link to abstract on Blood Journal

 

November 4, 2016 Events, Publications No comments yet